Interestingly, the differences between the nanoparticle-containing formulation and the other formulations were evidenced in this second phase, as shown in Figure 2 where differences between the formulations appear more significant after 2 h. This may suggest a higher and faster availability of CP from the NP formulation at the site of action that, in this case, is represented by the edema where the inflammatory cells are mainly located.